Patient characteristics and risk of bleeding with dabigatran in atrial fibrillation

JAMA Internal Medicine

Volumn 175, Issue 7, 2015, Pages 1245-

  Henriksen, Daniel Pilsgaard ^a   Hansen, Morten Rix ^b   Damkier, Per ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; DABIGATRAN; ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; WARFARIN;

AGED; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; EXTERNAL VALIDITY; HAZARD RATIO; HUMAN; HYPERTENSION; LETTER; MEDICARE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; FEMALE; MALE;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HEMORRHAGE; HUMANS; MALE; WARFARIN;

EID: 84937458816     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.1289     Document Type: Letter

References (3)

1. Hernandez I, Baik SH, Pi?era A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18-24.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
3. Larsen TB, Rasmussen LH, Skj?th F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J AmColl Cardiol. 2013;61(22): 2264-2273.